# Antimicrobial Resistance (AMR) Antimicrobial resistance occurs when microorganisms — bacteria, viruses, fungi, and parasites — evolve mechanisms that neutralise the action of antimicrobial agents that once controlled them. The WHO designates AMR among the top ten global health threats. By 2050, drug-resistant infections could cause 10 million deaths annually — exceeding cancer mortality — under current trajectory estimates (O'Neill Review, 2016). ## Resistance Mechanisms Bacteria evolve resistance through four principal mechanisms: **Enzymatic inactivation.** The organism produces enzymes that degrade or chemically modify the antimicrobial before it can act. Beta-lactamases hydrolyse the beta-lactam ring of penicillins and cephalosporins. Extended-spectrum beta-lactamases (ESBLs) have broadened to degrade third-generation cephalosporins. **Target modification.** Mutations alter the cellular structure the antimicrobial binds to, reducing affinity. MRSA (methicillin-resistant *Staphylococcus aureus*) expresses an altered penicillin-binding protein (PBP2a) with low affinity for beta-lactam antibiotics. **Efflux pumps.** Active transport proteins expel the antimicrobial from the cell faster than it accumulates. Efflux-mediated resistance is broad-spectrum — a single pump can confer resistance to multiple structurally unrelated compounds. **Reduced permeability.** Gram-negative bacteria reduce expression of outer membrane porins, decreasing intracellular drug concentration. *Pseudomonas aeruginosa* uses this mechanism alongside efflux pumps for multi-drug resistance. ## Why Natural Antimicrobials and ROS Are AMR-Relevant Synthetic antibiotics typically have a single molecular target — which creates a single point of evolutionary failure. Natural antimicrobials, particularly ROS-generating systems, attack multiple cellular targets simultaneously: - Membrane lipid peroxidation (structural disruption) - DNA strand breakage (replication failure) - Protein oxidation (enzyme inactivation) Evolving resistance to all three attack modes simultaneously requires multiple concurrent mutations — substantially less probable than the single mutation needed to resist a target-specific antibiotic. This multi-target mechanism is the scientific basis for the AMR narrative around natural antimicrobials. It is supported by in vitro evidence, though clinical evidence in human medicine is still limited. The food preservation application — where the aim is bacteriostasis or surface kill, not systemic treatment — places less evolutionary pressure on resistance development than therapeutic use. ## ESKAPE Pathogens The IDSA designates six nosocomial pathogens as the primary clinical face of the AMR crisis — collectively acronymed ESKAPE because they "escape" available therapies: | Organism | Resistance Profile | Primary Concern | |---|---|---| | *Enterococcus faecium* | Vancomycin-resistant (VRE) | Hospital-acquired bloodstream infection | | *Staphylococcus aureus* | Methicillin-resistant (MRSA) | Wound, skin, bloodstream infections | | *Klebsiella pneumoniae* | Carbapenem-resistant (CRE) | Ventilator-associated pneumonia | | *Acinetobacter baumannii* | Multidrug-resistant | ICU infections; almost no treatment options | | *Pseudomonas aeruginosa* | Multidrug-resistant | Burn wounds, CF patients | | *Enterobacter* spp. | ESBL-producing | Urinary and bloodstream infections | ESKAPE organisms are relevant to natural antimicrobials not because natural antimicrobials will replace antibiotics in systemic treatment — they will not, and claiming otherwise is scientifically reckless — but because surface contamination control in healthcare environments, food processing facilities, and packhouses creates demand for effective biocidal agents that do not accelerate ESKAPE resistance. ## Biofilm Resistance Biofilms are structured microbial communities encased in a self-produced extracellular polymeric substance (EPS) matrix, adhered to surfaces. Biofilm bacteria are 100–1,000× more resistant to antibiotics and sanitisers than planktonic cells. Three mechanisms drive biofilm resistance: **Diffusion limitation.** The EPS matrix restricts penetration of antimicrobial agents. By the time an agent reaches the deep layers of a biofilm, its effective concentration may be sub-inhibitory — enough to select for resistance, not enough to kill. **Persister cells.** A subpopulation of metabolically dormant cells survive antibiotic treatment because antibiotics target active metabolic processes. When treatment stops, persisters repopulate the biofilm. **Quorum sensing.** Coordinated gene expression across the biofilm community upregulates resistance and EPS production in response to environmental signals — including the presence of antimicrobial agents. In food processing environments, biofilms on stainless steel, conveyor belts, and cold room surfaces form persistent contamination reservoirs. Conventional quaternary ammonium compound (QAC) sanitisers kill planktonic cells efficiently but fail to eradicate established biofilms. Iron oxide nanoparticles and ROS-generating systems show in vitro biofilm disruption activity, potentially addressing the biofilm problem that chemical sanitisers cannot. ## The Agricultural AMR Pathway Sub-therapeutic antibiotic use in animal agriculture is a primary driver of AMR propagation. Antibiotics used as growth promoters and prophylactics create selective pressure for resistant strains that then enter the food chain and the environment. Replacing synthetic preservatives and sanitisers with natural antimicrobials in food production reduces antibiotic use in the supply chain — indirectly reducing AMR selective pressure. This argument is increasingly prominent in procurement specifications for sustainably positioned food brands. ## Regulatory and Policy Tailwinds - **EU Action Plan on AMR (2017):** calls for reduction of antimicrobial use in food-producing animals and promotion of alternatives - **WHO Global Action Plan on AMR (2015):** member states committed to national action plans including monitoring antibiotic use in agriculture - **UK Veterinary Antibiotic Resistance and Sales Surveillance (VARSS):** annual reporting on antibiotic use in food animal sectors These frameworks create institutional demand for documented AMR-sparing alternatives — a regulatory tailwind for natural antimicrobial products that can credibly claim an AMR benefit. --- *Part of [[Natural Antimicrobials & Sustainable Materials MOC]]*